Bexarotene monotherapy for patient with refractory early stage mycosis fungoides
DOI:
https://doi.org/10.66344/jpad.v24i4.225Keywords:
Mycosis fungoides, bexarotene, treatment, diagnosisAbstract
Mycosis fungoides (MF) is a subtype of cutaneous T-Cell lymphoma and oftenly difficult to treat. We report a case of mycosis fungoides in which several lines of therapy were employed including both skin-directed and systemic treatment strategies with no clinical remission. This case highlights MF’s insidious onset. In this patient, the early stage of disease was marked by erythematous plaque and misdiagnosed as tinea corporis. The lack of symptomatic control led to biopsy of the lesion, which in turn precipitated the accurate diagnosis of MF. Several lines of treatment were initiated with unsatisfactory outcomes. Bexarotene therapy was started and good clinical and histological response was observed. We conclude bexarotene as salvage therapy is an efficacious therapeutic option for this patient with plaque mycosis fungoides and its safety profile is favorable for long-term use.
References
1. Scarisbrick JJ, Whittaker S, Evans AV et al. Prognosis significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood. 2001;97:624-30.
2. Zackheim HS, Kashani-Sabet M, McMillan A. Low dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003;49:873-8.
3. Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:581-93.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Husein Husein-ElAhmed, Maria-Teresa Gutierrez-Salmerón, Jose Aneiros-Cachaza, Valentín Garcia-Mellado
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
